CTX110

CTX110 is an investigational, healthy donor-derived, gene-edited allogeneic CAR-T cell therapy developed by CRISPR Therapeutics. It uses CRISPR/Cas9 technology to engineer T cells that express a chimeric antigen receptor (CAR) targeting the B-lymphocyte antigen CD19 (CD19), which is commonly found on B-cell malignancies. Unlike autologous CAR-T therapies that use a patient’s own cells, CTX110 is derived from healthy donors and designed as an "off-the-shelf" product for rapid administration. The therapy aims to induce anti-tumor activity in relapsed or refractory CD19-positive B-cell malignancies such as large B-cell lymphoma and adult acute lymphocytic leukemia[1][3][4][7]. Early clinical trials have shown dose-dependent anti-tumor responses.

Other names

allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD19 antigen